Analytical Data
-
Gene name
PRAMEF5
- Application
-
Alternative Names
PRAMEF5; PRAMEF23; PRAMEF5L; PRAME family member 5
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5TYX0
-
Expression Region
1-476 aa
-
AA Sequence
MSIRTPPRLL ELAGRSLLRD QALAMSTLEE LPTELFPPLF MEAFSRRRCE ALKLMVQAWP FRRLPLRPLI KMPCLEAFQA VLDGLDALLT QGVHPRRWKL QVLDLQDVCE NFWMVWSEAM AHGCFLNAKR NKKPVQDCPR MRGQQPLTVF VELWLKNRTL DEYLTCLLLW VKQRKDLLHL CCKKLKILGM PFRNIRSILK MVNLDCIQEV EVNCKWVLPI LTQFTPYLGH MRNLQKLVLS HMDVSRYVSP EQKKEIVTQF TTQFLKLCCL QKLSMNSVSF LEGHLDQLLS CLKTSLKVLT ITNCVLLESD LKHLSQCPSI SQLKTLDLSG IRLTNYSLVP LQILLEKVAA TLEYLDLDDC GIIDSQVNAI LPALSRCFEL NTFSFCGNPI SMATLENLLS HTIILKNLCV ELYPAPRESY DADGTLCWSR FAQIRAELMK RVRDLRHPKR ILFCTDCCPD CGNRSFYDLE ADQCCC
-
Molecular Weight
54.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PRAMEF5, a member of the cancer/testis antigen family, has garnered significant attention in cancer research due to its differential expression patterns in various tumors and limited presence in normal tissues, specifically in the testis. This unique expression profile makes PRAMEF5 an attractive target for immunotherapy and cancer diagnostics. Research suggests that PRAMEF5 may play a role in tumorigenesis and could potentially be involved in the modulation of the immune response against cancer cells. Previous studies have demonstrated that PRAMEF5 can induce T-cell responses, indicating its potential as a candidate for peptide-based vaccines. The reconstitution of PRAMEF5 as a recombinant protein allows for in-depth studies of its immunogenicity and function in a controlled laboratory setting. Moreover, understanding the molecular mechanisms underlying PRAMEF5 expression could provide insights into its role in cancer biology and aid in the development of novel therapeutic strategies aimed at harnessing the immune system to target tumors. This research not only paves the way for potential clinical applications but also enhances the overall understanding of the immune landscape in cancer, positioning PRAMEF5 as a significant player in the field of tumor immunology.
